Australian biotechs attract strong interest at US investor meeting

By AusBiotech
Monday, 23 January, 2012

For the fifth year, AusBiotech has managed a presentation of Australian companies to San Francisco for an investor showcase held in conjunction with invitation-only the 30th JP Morgan Annual Healthcare Conference in the US.

The event held on the 9 January was again successful in attracting investors – this year 280, with a large contingent from China and Hong Kong – providing a valuable platform for Australian companies seeking investment and partnerships. Presenting companies included:

  • Alchemia (ASX:ACL)
  • Genetic Technologies (ASX:GTG)
  • Phylogica (ASX:PYC)
  • Sunshine Heart (ASX:SHC)
  • Uptake Medical
  • Viveve

AusBiotech has established a calendar of international and local investor showcase events. The next events on the international calendar are:

  • Australian Life Science Showcase: Hong Kong 2012 - Wednesday 23 May 2012
  • Australian Life Science Showcase: New York 2012 - Friday 15 June 2012 (just prior to BIO2012 convention in Boston)
  • Australian Life Science Showcase: Edinburgh 2012 -Wednesday 3 October 2012
  • Australian Life Science Showcase: London 2012 - Friday 5 October 2012

Upcoming local events include:

  • ‘Brokers meet Biotech' Luncheon - Tuesday 28 February 2012, Melbourne, Victoria
  • Medtech Investment Showcase - Monday 14 May 2012 (preceding AusMedtech annual conference), Sydney
  • Australasian Life Sciences Investment Summit 2012 - Friday 2 November (part of the AusBiotech 2012 conference), Melbourne

For further information see www.ausbiotech.org/investment.

Related News

Proposed Australian trial eyes up blood testing for Alzheimer's

Utilising networks of GPs across three states, a large-scale study intends on combining digital...

Applications open for $300K pandemic therapeutics fellowships

Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...

CTA granted for CAR-T cell therapy for multiple myeloma

The Therapeutic Goods Administration has granted Clinical Trial Approval for KMCAR T-cell...


  • All content Copyright © 2026 Westwick-Farrow Pty Ltd